At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PRME Prime Medicine, Inc.
Closed 11-25 16:00:00 EST
3.33
+0.13
+4.06%
盘后3.35
+0.02+0.60%
19:02 EST
High3.53
Low3.25
Vol1.67M
Open3.25
D1 Closing3.20
Amplitude8.75%
Mkt Cap424.89M
Tradable Cap176.51M
Total Shares127.60M
T/O5.60M
T/O Rate3.14%
Tradable Shares53.01M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Prime Medicine, Inc. (PRME) Gets a Hold from Morgan Stanley
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.